Experts Warn of Hidden Psychological Burden in Glaucoma
Patients with glaucoma have a notable burden of depression and anxiety that often goes undetected, highlighting a critical gap in healthcare, the researchers found. These psychological comorbidities were linked to worse general health and poorer quality of life due to visual impairment and occurred more commonly among women, younger patients, and those with lower incomes.
METHODOLOGY:
Researchers conducted a cross-sectional study to assess the prevalence of anxiety and depression among individuals diagnosed with glaucoma and to identify risk factors associated with these psychological comorbidities.
They analyzed data of 249 adult patients with glaucoma (mean age, 60.49 years; 54.6% women) who were interviewed at an eye hospital in Germany using a three‐part standardized questionnaire.
The questionnaire asked for details on demographics, medical history, and ocular health including clinical data on glaucoma and assessed symptoms of depression and anxiety as well as the effect of overall health and visual impairment on quality of life.
TAKEAWAY:
Although only 11.2% of patients with glaucoma had a prior diagnosis of depression and 1.2% had a prior diagnosis of anxiety, screening revealed significantly higher rates of symptoms of both anxiety (42.2%) and depression (34.9%; P < .001) in this cohort.
Scores used for assessing depression showed a strong correlation with those used for assessing anxiety; a higher severity of depressive symptoms was associated with poorer mental and physical health, lower quality of life due to visual impairment, female sex, living alone, younger age, and lower incomes (P < .05 for all).
A higher severity of anxiety symptoms was also linked to poorer mental and physical health, lower quality of life due to visual impairment, female sex, and lower incomes (P < .05 for all).
IN PRACTICE:
'Incorporating routine psychometric screening into standard clinical practice is essential to facilitate early detection and treatment of psychological disorders,' the researchers reported.
'Effective collaboration among ophthalmologists, general practitioners, and psychologists is crucial to providing holistic, patient-centered care. Tailoring interventions to factors such as age, gender, vision impairment, and socioeconomic status can bridge existing social disparities and foster a more integrated and personalized care model,' they added.
SOURCE:
This study was led by Alexander Christopher Rokohl, MD, of the Department of Ophthalmology at the University of Cologne, Cologne, Germany. It was published online on July 17, 2025, in the British Journal of Ophthalmology.
LIMITATIONS:
This study took place in a tertiary setting that usually treated patients with more severe glaucoma. The cohort showed demographic bias toward older European participants. Individuals without sufficient proficiency in German were excluded from the analysis, although they may have had less access to medical help because of language or culture issues.
DISCLOSURES:
No funding was received for this research. No relevant conflicts of interest were disclosed.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
2 hours ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
Yahoo
2 hours ago
- Yahoo
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.
